730
Single nucleotide polymorphisms (SNP) (cont.)
MIP probes , 67
mitochondrial SNPs , 68–69
NanoChip, use of , 64
PCR-CTPP , 65–66
pyrosequencing , 67
SMAP 2 , 68
SNP-IT primer-extension technology , 64
TaqMan real-time PCR method , 66
ZFPs , 68
clinical trials, role in , 59
copy number variation , 11–12
disease susceptibility and drug response , 58
genotyping and haplotyping , 69–70
defi nition , 59
HapMap, drug response , 62
limitations , 60, 69
linkage disequilibrium (LD) methods , 60
whole-genome sequencing , 60–62
INDELS , 13–14
markers, uses of , 10–11
personalized medicine , 58, 59, 70
polymorphisms , 10
structural variations , 15, 16
systems biology , 26
technologies for , 62, 63
Single-photon emission computed tomography
(SPECT) , 578, 579
Sipuleucel-T , 240–241
Skin disorders
androgenetic alopecia , 570
skin care, genetic testing for , 569–570
Sleep disorders , 454–455
Small interfering RNAs (siRNAs) , 195
Smart amplifi cation process version 2
(SMAP 2) , 68
Smoothened homologue (SMO) , 290, 291
SNaPshot Multiplex System , 210
SNP. See Single nucleotide
polymorphisms (SNP)
SNP-IT primer-extension technology , 64
Southeast Nebraska Cancer Center , 624–625
Sphingolipids , 259, 260, 538
Spinocerebellar ataxia , 161–162
SPOT-Light ® HER2 CISH Kit , 302
SSRIs. See Selective serotonin reuptake
inhibitors (SSRIs)
Stable isotope-based dynamic metabolic
profi ling (SIDMAP) , 273–274
Stanford Center for Genomics and
Personalized Medicine , 625
Statistically aided, long-read haplotyping
(SLRH) , 61–62
Stem cells
drug testing , 193
ESCs , 191
gene therapy, cancer , 193–194
iPSC technology , 191
unfertilized embryos , 192
Steroid receptor coactivator 3 (SRC-3) , 295
Stroke
chronic post-stroke stage
cell therapy, role of , 439, 440
hyperbaric oxygen , 438, 440
conventional risk factors , 437
incidence rate , 437
intracerebral hemorrhage , 438
proteomics , 437
restorative therapies , 438
Structural variations (SVs) , 10, 15–17
Suprachiasmatic nuclei (SCN) , 180
Surface-enhanced laser desorption/ionization
(SELDI) process , 53–54
Surgery , 585–586
Sweat Cl- test , 547
Synthetic biology , 29–30
Systemic lupus erythematosus (SLE) , 553–554
Systems biology , 624
defi nition of , 26–27
medicine , 28–29
pharmacology , 27T
TaqMan real-time PCR method , 66, 69
TargetPrint ® , 309
Ted Rogers Centre for Heart Research , 628
The Cancer Genome Atlas (TCGA) , 323–324,
342, 365–366
The Center for the Advancement of Genomics
(TCAG) , 616–617
Therapeutics for Rare and Neglected Diseases
(TRND) program , 610
Thiopurine methyltransferase (TPMT) , 142,
267, 327–328, 553
Thrombotic disorders
anticoagulant therapy , 503–504
antiplatelet therapy , 504–505
factor V Leiden mutation , 502–503
Thyroid cancer , 364
Tissue Systems Biology (TSB™) , 231
Topoisomerase-I (TOP1) , 344
Toxicoproteomics
hepatotoxicity , 166–167
nephrotoxicity , 167
neurotoxicity , 167Index